US20100152179A9 - Treatment of central nervous system disorders - Google Patents

Treatment of central nervous system disorders Download PDF

Info

Publication number
US20100152179A9
US20100152179A9 US12/195,937 US19593708A US2010152179A9 US 20100152179 A9 US20100152179 A9 US 20100152179A9 US 19593708 A US19593708 A US 19593708A US 2010152179 A9 US2010152179 A9 US 2010152179A9
Authority
US
United States
Prior art keywords
adamantane
amino
methyl
carboxamide
methylpropanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/195,937
Other languages
English (en)
Other versions
US20090054426A1 (en
Inventor
R. Scott Bitner
Kaitlin E. Browman
Michael E. Brune
Yixian Chen
Jurgen Dinges
Karla Drescher
Peer Jacobson
Hwan-Soo Jae
Ravi Kurukulasuriya
James T. Link
David J. Madar
Jyoti R. Patel
Marina A. Pliushchev
Jeffrey J. Rohde
Lynne E. Rueter
Qi Shuai
Bryan K. Sorensen
Jiahong Wang
Karsten M. Wicke
Martin Winn
Dariusz Wodka
Vince Yeh
Hong Yong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/697,044 external-priority patent/US7435833B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US12/195,937 priority Critical patent/US20100152179A9/en
Assigned to ABBOTT LABORATORIES reassignment ABBOTT LABORATORIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YEH, VINCE, MADAR, DAVID J., BROWMAN, KAITLIN E., DINGES, JURGEN, PLIUSHCHEV, MARINA A., WONG, JIAHONG, DRESCHER, KARLA, WODKA, DARIUSZ, WICKE, KARSTEN M., CHEN, YIXIAN, SHUAI, QI, JAE, HWAN-SOO, KURUKULASURIYA, RAVI, LINK, JAMES T., WINN, MARTIN, JACOBSON, PEER, YONG, HONG, BRUNE, MICHAEL E., PATEL, JYOTI R., ROHDE, JEFFREY J., RUETER, LYNNE E., BITNER, R. SCOTT, SORENSEN, BRYAN K.
Priority to US12/390,329 priority patent/US8415354B2/en
Priority to US12/390,286 priority patent/US8198331B2/en
Priority to US12/390,318 priority patent/US20090192198A1/en
Publication of US20090054426A1 publication Critical patent/US20090054426A1/en
Publication of US20100152179A9 publication Critical patent/US20100152179A9/en
Priority to US13/469,021 priority patent/US8993632B2/en
Priority to US13/530,422 priority patent/US8716345B2/en
Priority to US13/554,698 priority patent/US8940902B2/en
Priority to US13/782,054 priority patent/US9133145B2/en
Priority to US14/226,615 priority patent/US9290444B2/en
Priority to US14/569,203 priority patent/US9464072B2/en
Priority to US14/671,030 priority patent/US20150265613A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
US12/195,937 2004-04-29 2008-08-21 Treatment of central nervous system disorders Abandoned US20100152179A9 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US12/195,937 US20100152179A9 (en) 2006-04-07 2008-08-21 Treatment of central nervous system disorders
US12/390,329 US8415354B2 (en) 2004-04-29 2009-02-20 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US12/390,286 US8198331B2 (en) 2005-01-05 2009-02-20 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US12/390,318 US20090192198A1 (en) 2005-01-05 2009-02-20 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US13/469,021 US8993632B2 (en) 2005-01-05 2012-05-10 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US13/530,422 US8716345B2 (en) 2005-01-05 2012-06-22 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US13/554,698 US8940902B2 (en) 2006-04-07 2012-07-20 Treatment of central nervous system disorders
US13/782,054 US9133145B2 (en) 2004-04-29 2013-03-01 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US14/226,615 US9290444B2 (en) 2005-01-05 2014-03-26 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US14/569,203 US9464072B2 (en) 2006-04-07 2014-12-12 Treatment of central nervous system disorders
US14/671,030 US20150265613A1 (en) 2005-01-05 2015-03-27 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79014106P 2006-04-07 2006-04-07
US11/697,044 US7435833B2 (en) 2006-04-07 2007-04-05 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US95708207P 2007-08-21 2007-08-21
US12/195,937 US20100152179A9 (en) 2006-04-07 2008-08-21 Treatment of central nervous system disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/697,044 Continuation-In-Part US7435833B2 (en) 2006-04-07 2007-04-05 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Related Child Applications (7)

Application Number Title Priority Date Filing Date
US11/119,022 Continuation-In-Part US7880001B2 (en) 2004-04-29 2005-04-29 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US11/325,965 Continuation-In-Part US7511175B2 (en) 2005-01-05 2006-01-05 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US11/326,277 Continuation-In-Part US7217838B2 (en) 2005-01-05 2006-01-05 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US12/390,329 Continuation-In-Part US8415354B2 (en) 2004-04-29 2009-02-20 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US12/390,318 Continuation-In-Part US20090192198A1 (en) 2005-01-05 2009-02-20 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US12/390,286 Continuation-In-Part US8198331B2 (en) 2005-01-05 2009-02-20 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US13/554,698 Continuation US8940902B2 (en) 2006-04-07 2012-07-20 Treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
US20090054426A1 US20090054426A1 (en) 2009-02-26
US20100152179A9 true US20100152179A9 (en) 2010-06-17

Family

ID=40378988

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/195,937 Abandoned US20100152179A9 (en) 2004-04-29 2008-08-21 Treatment of central nervous system disorders
US13/554,698 Expired - Fee Related US8940902B2 (en) 2006-04-07 2012-07-20 Treatment of central nervous system disorders
US14/569,203 Expired - Fee Related US9464072B2 (en) 2006-04-07 2014-12-12 Treatment of central nervous system disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/554,698 Expired - Fee Related US8940902B2 (en) 2006-04-07 2012-07-20 Treatment of central nervous system disorders
US14/569,203 Expired - Fee Related US9464072B2 (en) 2006-04-07 2014-12-12 Treatment of central nervous system disorders

Country Status (3)

Country Link
US (3) US20100152179A9 (fr)
JP (2) JP5736098B2 (fr)
WO (1) WO2009026422A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277647A1 (en) * 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US9133145B2 (en) 2004-04-29 2015-09-15 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
EP2243479A3 (fr) 2009-04-20 2011-01-19 Abbott Laboratories Nouvel amide et dérivés d'amidine et utilisations associées
MX2011011082A (es) * 2009-04-20 2011-11-04 Abbott Lab Derivados de amida y amidina novedosos y usos de los mismos.
EP2322163A1 (fr) * 2009-11-03 2011-05-18 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2399926A1 (fr) * 2010-06-22 2011-12-28 Justus-Liebig-Universität Giessen Peptides comportant 3-aminoadamantane acides carboxyliques améliorent la plasticité synaptique et agissent comme agents neurogène
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR101332805B1 (ko) 2011-03-31 2013-11-27 한국화학연구원 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2014192865A1 (fr) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Dérivé phénylpipérazine
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
UA126829C2 (uk) * 2018-03-01 2023-02-08 Такеда Фармасьютікал Компані Лімітед Піперидиніл-3-(арилокси)пропанаміди та пропаноати
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
WO2023235937A1 (fr) * 2022-06-10 2023-12-14 Actinogen Medical Limited Traitement de sujets résistants aux antidépresseurs

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273704A (en) * 1979-12-03 1981-06-16 G. D. Searle & Co. N-Adamantane-substituted tetrapeptide amides
US4324791A (en) * 1975-01-16 1982-04-13 A. H. Robins Company, Inc. Heterocyclic antidiarrheal compositions & methods of use
US4514332A (en) * 1984-04-16 1985-04-30 G. D. Searle & Co. Tetrapeptide adamantyl amides
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4921958A (en) * 1989-04-22 1990-05-01 American Home Products Corporation Piperazinylalkylcarboxylic acid adamantylamides
US5397788A (en) * 1990-08-31 1995-03-14 Warner-Lambert Company Amino acid derivatives cyclized at the C-terminal
US5622983A (en) * 1989-06-29 1997-04-22 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives
US6368816B2 (en) * 1995-08-29 2002-04-09 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040133011A1 (en) * 2002-12-20 2004-07-08 Waddell Sherman T. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US6784167B2 (en) * 2000-09-29 2004-08-31 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-II inhibitors
US20050245534A1 (en) * 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050277647A1 (en) * 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
US20060004049A1 (en) * 2004-06-24 2006-01-05 Wenqing Yao N-substituted piperidines and their use as pharrmaceuticals
US20060000947A1 (en) * 2004-07-01 2006-01-05 Emil Jacob Passenger sitting/sleeping arrangement
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060079506A1 (en) * 2002-12-23 2006-04-13 Linders Joannes T M Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
US20060089349A1 (en) * 2003-02-07 2006-04-27 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active compounds
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20060100235A1 (en) * 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US20060106008A1 (en) * 2003-04-11 2006-05-18 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US20060106071A1 (en) * 2002-12-19 2006-05-18 Lin Linus S Substituted amides
US20060111348A1 (en) * 2003-04-11 2006-05-25 Novo Nordisk A/S Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
US20060149070A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20060281773A1 (en) * 2005-01-05 2006-12-14 Patel Jyoti R Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20070161641A1 (en) * 2001-02-16 2007-07-12 Aventis Pharmaceuticals Inc. Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
US20080064693A1 (en) * 2004-08-30 2008-03-13 Libuse Jaroskova N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors
US7435833B2 (en) * 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614716B2 (en) 1985-08-14 1991-09-12 G.D. Searle & Co. Phenyl substituted dipeptide amides
EP0442878A4 (en) 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
NZ234264A (en) 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions
WO1991013081A1 (fr) 1990-02-28 1991-09-05 Teikoku Seiyaku Kabushiki Kaisha Substance physiologiquement active capable de passer a travers une biomembrane
ATE288262T1 (de) 1991-02-08 2005-02-15 Scion Pharmaceuticals Inc Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung
CA2091194A1 (fr) 1992-04-08 1993-10-09 Richard D. Connell Derives 2-oxoethyliques utilises comme immunosuppresseurs
US5576355A (en) 1993-06-04 1996-11-19 Mobil Oil Corp. Diamondoid derivatives for pharmaceutical use
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
AU8278498A (en) 1997-07-07 1999-02-08 Cambridge Neuroscience, Inc. Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
CA2371618A1 (fr) 1999-04-28 2000-11-09 Yuji Ishihara Composes d'amides cycliques, leurs procedes de preparation et d'utilisation
MXPA02005100A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de pirazol antagonistas de receptor de canabinoide.
AU2002350366A1 (en) 2001-12-31 2003-07-30 Actelion Pharmaceuticals Ltd. Pyrrolidone carboxamides
WO2003065983A2 (fr) 2002-02-01 2003-08-14 Merck & Co., Inc. Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
WO2003075660A1 (fr) 2002-03-06 2003-09-18 Merck & Co., Inc. Methode de traitement ou de prevention de l'obesite
US6793240B2 (en) 2002-07-25 2004-09-21 Autoliv Asp, Inc. Expandable section for inflatable curtains
AU2003269242A1 (en) 2002-10-11 2004-05-04 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
PL376301A1 (en) 2002-10-24 2005-12-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1615698B1 (fr) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC Nouvelles amides substitues et leur utilisation pharmaceutique
EP1615697A2 (fr) 2003-04-11 2006-01-18 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees
WO2004089416A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
EP1615637A1 (fr) 2003-04-11 2006-01-18 Novo Nordisk A/S Utilisation pharmaceutique de 1,2,4-triazoles substituees
WO2004113310A1 (fr) 2003-06-25 2004-12-29 Biovitrum Ab Utilisation d'un inhibiteur de compose de type 1 11-b-hydroxysteroide deshydrogenase type 1 destine a faciliter la cicatrisation d'une plaie
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
CA2540843A1 (fr) 2003-10-23 2005-05-12 Sterix Limited Derives de carboxamide de phenyle et de sulfonamide utilisables comme 11-beta-hydroxysteroide deshydrogenase
US20070274916A1 (en) * 2003-10-24 2007-11-29 Janet Clark Method for Identifying Compounds that Affect Expression of Tryptophan Hydroxylase Isoform 2
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
WO2005060963A1 (fr) 2003-12-19 2005-07-07 Pfizer Inc. Derives de benzenesulfonylamino-pyridin-2-yl et composes apparentes en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase type 1 (11-beta-hsd-1) pour le traitement du diabete et de l'obesite
JP2007261945A (ja) 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
GB0408771D0 (en) 2004-04-20 2004-05-26 Sterix Ltd Compound
MXPA06012831A (es) 2004-05-06 2007-01-26 Pfizer Nuevos compuestos de derivados de morfolina y prolina.
DE602005007344D1 (de) 2004-05-07 2008-07-17 Janssen Pharmaceutica Nv Adamantyl pyrrolidin-2-on-derivate als 11-beta hydroxysteroid dehydrogenas inhibitoren
EA014419B1 (ru) 2004-05-24 2010-12-30 Эмджен Инк. 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
JP2008504274A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
KR20070024639A (ko) 2004-06-24 2007-03-02 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
PT1773768T (pt) 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
JP2008509146A (ja) 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのスルホニル化合物
US20060122197A1 (en) 2004-08-10 2006-06-08 Wenqing Yao Amido compounds and their use as pharmaceuticals
EP1786774B1 (fr) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Derives de lactame tricyclique utilises en tant qu'inhibiteurs de 11-beta-hydroxysteroide deshydrogenase
EP1802623A1 (fr) 2004-10-12 2007-07-04 Novo Nordisk A/S Composes spiro actifs du type a- hydroxysteroide deshydrogenase de type 1
EP1807072B1 (fr) 2004-10-29 2009-01-07 Eli Lilly And Company Inhibiteurs de la 11-béta-hydroxystéroïde déshydrogénase 1 dérivés de cycloalkyllactames
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
EP1666467A1 (fr) 2004-11-08 2006-06-07 Evotec AG Inhibiteurs de 11-béta-HSD1
EP1659113A1 (fr) 2004-11-08 2006-05-24 Evotec AG Inhibiteurs de 11 beta hydroxy stéroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (fr) 2004-11-08 2006-05-10 Evotec OAI AG Inhibiteurs de 11béta-HSD1
KR101368228B1 (ko) 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
JPWO2006104280A1 (ja) 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324791A (en) * 1975-01-16 1982-04-13 A. H. Robins Company, Inc. Heterocyclic antidiarrheal compositions & methods of use
US4273704A (en) * 1979-12-03 1981-06-16 G. D. Searle & Co. N-Adamantane-substituted tetrapeptide amides
US4514332A (en) * 1984-04-16 1985-04-30 G. D. Searle & Co. Tetrapeptide adamantyl amides
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4921958A (en) * 1989-04-22 1990-05-01 American Home Products Corporation Piperazinylalkylcarboxylic acid adamantylamides
US5622983A (en) * 1989-06-29 1997-04-22 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives
US5397788A (en) * 1990-08-31 1995-03-14 Warner-Lambert Company Amino acid derivatives cyclized at the C-terminal
US7122531B2 (en) * 1995-08-29 2006-10-17 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
US7087400B2 (en) * 1995-08-29 2006-08-08 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
US6368816B2 (en) * 1995-08-29 2002-04-09 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
US6784167B2 (en) * 2000-09-29 2004-08-31 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-II inhibitors
US20070161641A1 (en) * 2001-02-16 2007-07-12 Aventis Pharmaceuticals Inc. Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20060106071A1 (en) * 2002-12-19 2006-05-18 Lin Linus S Substituted amides
US20040133011A1 (en) * 2002-12-20 2004-07-08 Waddell Sherman T. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20060079506A1 (en) * 2002-12-23 2006-04-13 Linders Joannes T M Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
US20060089349A1 (en) * 2003-02-07 2006-04-27 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active compounds
US20060111366A1 (en) * 2003-04-11 2006-05-25 Novo Nordisk A/S Pharmaceutical use of substituted amides
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20060100235A1 (en) * 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US20060106008A1 (en) * 2003-04-11 2006-05-18 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US20060111348A1 (en) * 2003-04-11 2006-05-25 Novo Nordisk A/S Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
US20050245534A1 (en) * 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050277647A1 (en) * 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20060004049A1 (en) * 2004-06-24 2006-01-05 Wenqing Yao N-substituted piperidines and their use as pharrmaceuticals
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060000947A1 (en) * 2004-07-01 2006-01-05 Emil Jacob Passenger sitting/sleeping arrangement
US20080064693A1 (en) * 2004-08-30 2008-03-13 Libuse Jaroskova N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors
US20060149070A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7217838B2 (en) * 2005-01-05 2007-05-15 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20060281773A1 (en) * 2005-01-05 2006-12-14 Patel Jyoti R Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7435833B2 (en) * 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cecil Textbook of Medicine, 20th edition (1996), Vol..2, pages 1992-1996. *
Cecil Textbook of Medicine, 20th edition (1996), Vol..2, pages 2050-2057. *
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on 2003-09-23]. Retrieved from the Internet, URL;http://www.cnn.com/2003/HEALTH/conditions/O9/24/alzheimers.drug.ap/indexhtml> *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277647A1 (en) * 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8372841B2 (en) 2004-04-29 2013-02-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US9133145B2 (en) 2004-04-29 2015-09-15 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Also Published As

Publication number Publication date
WO2009026422A2 (fr) 2009-02-26
US8940902B2 (en) 2015-01-27
WO2009026422A3 (fr) 2009-04-30
US20150099740A1 (en) 2015-04-09
US20090054426A1 (en) 2009-02-26
JP2013209377A (ja) 2013-10-10
JP5736098B2 (ja) 2015-06-17
US20130059829A1 (en) 2013-03-07
JP2009046464A (ja) 2009-03-05
US9464072B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
US9464072B2 (en) Treatment of central nervous system disorders
CN106068256B (zh) 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
KR101235863B1 (ko) 11-베타-하이드록시스테로이드 데하이드로게나아제 타입 1효소의 억제제로서의 아다만틸-아세트아미드 유도체
US20050261302A1 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
WO2011068927A2 (fr) Inhibiteurs de la 11-β-hydroxystéroïde déshydrogénase de type 1 (11b-hsd1) et leurs utilisations
JP5916746B2 (ja) 認知障害を処置するためのピリダジン誘導体、組成物、および方法
CN108602821A (zh) 1h-咪唑并[4,5-b]吡啶基和2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶基杂环bet溴结构域抑制剂
JP2013542266A (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法
CA3075705A1 (fr) Amines heterocycliques beta-hydroxy et leur utilisation dans le traitement de l'hyperglycemie
US9133145B2 (en) Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
JP5744203B2 (ja) オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
CN115175911A (zh) 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
EP3368040B1 (fr) Méthodes et compositions pour récupérer d'un accident vasculaire cérébral
US9427439B1 (en) Methods and compositions for recovery from stroke
US20050245532A1 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050245533A1 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
JP2019504016A (ja) アルキルジヒドロキノリンスルホンアミド化合物
US20050245745A1 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
KR20210014164A (ko) 히스타민-3 수용체 역작용제에 의한 치료 방법
US20150265613A1 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN109640975B (zh) 组胺-3受体反向激动剂与乙酰胆碱酯酶抑制剂的组合
CN109562180B (zh) 组胺-3受体反向激动剂、乙酰胆碱酯酶抑制剂和nmda受体拮抗剂的三重组合产品
US20240010620A1 (en) Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereof
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT LABORATORIES, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BITNER, R. SCOTT;BROWMAN, KAITLIN E.;BRUNE, MICHAEL E.;AND OTHERS;REEL/FRAME:021781/0183;SIGNING DATES FROM 20081003 TO 20081031

Owner name: ABBOTT LABORATORIES,ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BITNER, R. SCOTT;BROWMAN, KAITLIN E.;BRUNE, MICHAEL E.;AND OTHERS;SIGNING DATES FROM 20081003 TO 20081031;REEL/FRAME:021781/0183

Owner name: ABBOTT LABORATORIES, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BITNER, R. SCOTT;BROWMAN, KAITLIN E.;BRUNE, MICHAEL E.;AND OTHERS;SIGNING DATES FROM 20081003 TO 20081031;REEL/FRAME:021781/0183

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION